Body dysmorphia questionnaire

Key Takeaways

Body dysmorphia questionnaire (BDDQ) is a validated 8-item screening tool developed by Dr Katharine Phillips that identifies suspected BDD in clinical settings within minutes.

A positive BDDQ screen requires follow-up diagnostic assessment; the questionnaire is a screening instrument, not a diagnostic tool, and should not be used alone to diagnose BDD.

Mental health clinicians and aesthetic practitioners should screen pre-procedure or pre-treatment to identify patients who may benefit from mental health support before pursuing appearance-focused interventions.

Pabau’s digital intake forms and automated workflows help embed BDD screening into consultation workflows, ensuring systematic assessment and documented screening records.

The body dysmorphia questionnaire (BDDQ) is a brief, evidence-based screening tool for identifying patients who may have body dysmorphic disorder. Developed by Dr Katharine Phillips at Brown University, the BDDQ has become the gold standard for rapid assessment in mental health, dermatology, and aesthetic practice settings across the US and UK.

This guide explains how to administer, score, and interpret the questionnaire, plus how to integrate it into your practice’s intake workflow.

What is body dysmorphic disorder (BDD)?

Body dysmorphic disorder is a mental health condition characterized by a preoccupation with perceived or slight flaws in physical appearance that are not observable or appear slight to others. The preoccupation is accompanied by repetitive behaviors (mirror checking, excessive grooming, reassurance seeking) or mental acts (comparing appearance to others, rumination) that cause significant distress and interfere with daily functioning.

BDD affects an estimated 1-2% of the general population, with higher prevalence among patients seeking cosmetic procedures. Individuals with untreated BDD experience high rates of social isolation, occupational impairment, depression, and suicidality-making early identification and appropriate referral a critical component of ethical aesthetic and mental health practice.

The disorder is classified in DSM-5 as an obsessive-compulsive and related disorder, meaning it shares features with OCD and other conditions characterized by intrusive thoughts and compulsive responses. Understanding BDD’s clinical presentation helps practitioners distinguish it from normal appearance concerns, low self-esteem, or genuine cosmetic treatment needs. A structured mental health assessment framework is essential for accurate differentiation.

Signs and symptoms of body dysmorphia

BDD manifests across cognitive, behavioral, and functional domains. Clinicians should watch for the following cardinal symptoms when screening new patients:

• Appearance preoccupation: Intrusive thoughts about perceived appearance flaws; the person may spend hours per day fixated on one or multiple body parts (e.g. skin, nose, hair, body shape).
• Time and distress: The preoccupation consumes significant time (typically 1+ hour daily) and causes marked emotional distress, anxiety, or depression.
• Compulsive behaviors: Mirror checking (or mirror avoidance), excessive grooming, reassurance seeking from others, comparing appearance to others or photographs, camouflaging appearance with clothing or makeup.
• Functional impairment: The preoccupation interferes with social relationships, occupational/academic performance, or daily activities. Many patients avoid social situations, dating, or medical care due to appearance anxiety.
• Insight variability: Patients may acknowledge the preoccupation is excessive, or they may have poor insight and believe their appearance concerns are justified (a significant prognostic and referral consideration).

In aesthetic surgery contexts, BDD symptoms are a red flag indicating the patient may not benefit from the procedure and may experience worse distress post-procedure. Early identification prevents harm and enables appropriate mental health referral.

Overview of BDD assessment instruments

Multiple validated instruments exist for BDD assessment, each serving a distinct clinical purpose. The table below summarizes the main tools used in research and practice:

The BDDQ is the starting point for most practitioners. It is brief, self-administered, and has demonstrated good sensitivity and specificity as a screening tool, in the same way a validated depression inventory screens a different population. Patients scoring positive on the BDDQ should be referred for a full diagnostic interview with a mental health clinician.

The BDD-YBOCS severity scale

Once BDD is diagnosed, the BDD-YBOCS (Yale-Brown Obsessive Compulsive Scale Modified for BDD) quantifies symptom severity and tracks treatment response. Unlike the BDDQ, the BDD-YBOCS is clinician-administered and measures the intensity and time spent on BDD obsessions and compulsions across 12 items.

The BDD-YBOCS is scored on a 0-48 scale with four severity bands: Mild (below 24), moderate (24-29), severe (30-36), and extreme (37-48). These are the empirically validated 2025 cutoffs from Mataix-Cols and colleagues — co-authored by Katharine Phillips, drawing on 804 patients across 11 datasets — replacing the long-established bands used previously.

Clinicians administer this tool at baseline and then periodically during treatment to monitor progress and adjust intervention intensity as needed. Structured patient records integrate severity tracking directly into the clinical note, enabling longitudinal monitoring without extra data entry.

Screening for BDD in aesthetic and cosmetic surgery settings

Aesthetic and cosmetic practitioners should screen all new patients for BDD pre-procedure. Research indicates 7-15% of cosmetic surgery candidates screen positive for BDD, and literature consistently shows that untreated BDD patients have poor surgical outcomes and higher dissatisfaction rates. Pre-procedure consultation best practices now include systematic BDD screening as a standard of care.

The BDDQ-AS (Aesthetic Surgery version) is a distinct, separately validated 7-item instrument for this setting — not simply an adapted BDDQ. A positive screen warrants a compassionate conversation: Acknowledge the patient’s appearance concerns, explain that BDD is a treatable psychiatric condition unrelated to actual appearance, and recommend mental health referral before proceeding with elective procedures.

This protects both patient welfare and clinical liability.

What to do after a positive BDD screen

A positive BDDQ result initiates a structured referral pathway. First, communicate results to the patient with sensitivity and psychoeducation-many patients feel shame or fear around the BDD label. Explain that BDD is a recognized mental health condition with evidence-based treatments (cognitive behavioral therapy, selective serotonin reuptake inhibitors, or both).

Second, document the screen, score, and referral recommendation in the patient’s chart. Third, provide warm handoff to a mental health clinician-either via direct referral letter, contact information for local therapists, or your practice’s own patient engagement tools that send automated follow-up resources. Automated referral workflows reduce clinician burden and ensure no patient is lost to follow-up.

How Pabau supports BDD screening in clinical practice

Pabau’s practice management platform lets you embed the body dysmorphia questionnaire directly into your practice’s intake workflow. Digital intake forms can be customized to embed the BDDQ, with auto-scoring that flags positive screens and generates summary notes for your clinician dashboard. Once administered, results are stored in structured patient records alongside clinical history, treatment plans, and referral notes.

For aesthetic practices, mental health practice software capabilities allow you to configure pre-consultation workflows that trigger the BDDQ automatically for new cosmetic patients. Post-positive-screen, intake workflow integration enables automated alerts to staff and direct patient messaging with referral resources.

This systematic approach reduces clinician time, ensures consistency, and improves patient safety and satisfaction. Patient portal access also enables patients to download their BDDQ score and referral summary for their mental health provider.

Compliance and documentation requirements

Administering the BDDQ and storing a patient’s responses means you’re handling protected health information (PHI). If your practice is HIPAA-covered in the US, or handles patient data under GDPR in the UK/EU, make sure your intake form, storage, and access controls meet the applicable standards.

Screening responses, severity ratings, and any referral notes become part of the patient’s medical record and are subject to your usual record-retention policy.

Because BDD screening touches directly on mental health status and, in aesthetic settings, procedure eligibility, treat positive screens with the same confidentiality safeguards as any other behavioral health finding.

Restrict access to the relevant clinical staff, and keep the open-text responses to question 3 (what specifically bothers the patient about their appearance) inside the secure record rather than in loose notes or intake paperwork that isn’t filed.

If a full diagnostic interview confirms the condition, code the diagnosis using ICD-10 F45.22 (body dysmorphic disorder) in the patient’s chart.

The BDDQ screen itself isn’t billed under a dedicated code, but documenting the screening date, the responses against each of the eight items, and any referral against the encounter supports continuity of care and protects your practice if a screening decision is ever reviewed.

Structured patient records keep the screen, the severity ratings, and the referral outcome in one auditable file, rather than scattered across paper forms.

Conclusion

The body dysmorphia questionnaire is a brief, validated tool that improves patient safety and care quality across mental health, dermatology, and aesthetic practice settings. Early identification of BDD enables timely referral to mental health specialists and prevents unnecessary procedures that may worsen symptoms for patients with this condition.

Remember that a positive screen is a compound result — concern, preoccupation, and either at least moderate severity or functional interference — not a simple count of “yes” answers.

By embedding the BDDQ into your practice’s intake workflow, scoring it correctly, and pairing it with a documented referral pathway, you create a systematic, compassionate approach to BDD screening that benefits every patient while reducing clinician workload.

Key resources for BDD assessment

A few related templates and resources worth pairing with BDD screening in your workflow:

Continue your research

Want a comprehensive mental health intake tool? Biopsychosocial assessment template provides a comprehensive framework for mental health intake that can be paired with the BDDQ for full BDD diagnostic workup.

Need to document consent and ethical screening? Group therapy informed consent demonstrates best-practice consent documentation that protects both patients and clinicians when discussing sensitive mental health findings.

Looking to scale BDD screening across multiple locations? Multi-location practice management ensures all practices follow the same BDD screening protocol and centralizes referral coordination across sites.

Continue your research

• Binge eating disorder quiz — screens for another body-image-driven condition that frequently co-occurs with BDD.
• PHQ-9 and GAD-7 template — assesses depression and anxiety, the most common conditions accompanying BDD.
• Trauma questionnaire template — captures the trauma history that often underlies appearance-focused distress.

Frequently asked questions about BDD questionnaires